688278 Xiamen Amoytop Biotech
- 54.65
- +0.51+0.94%
Xiamen Amoytop Biotech News
Tebao Biotech (688278.SH): Currently, the company's main business products are mainly domestic sales
Gelonghui, May 23丨Tebao Biotech (688278.SH) recently said during a survey reception from institutional investors that currently the company's main business products are mainly domestic sales, accounting for 0.19% of overseas sales revenue in 2023. Some of the company's products have been approved for registration in some overseas countries, and in the future, the company will further expand its international business according to business conditions.
Tebao Biotech (688278.SH): Currently, the actual clinical use of Pegobin is still dominated by dominant groups
Gelonghui, May 23丨Tebao Biotech (688278.SH) recently said during a survey reception from institutional investors that currently the actual clinical use of Pegbin is still dominated by dominant groups. As multiple clinical cure studies for people infected with different chronic hepatitis B infections advance, it has been further discovered that people in the immune control period also have a high clinical cure rate, and the range of treatment groups will gradually expand as clinical research and scientific research continue to advance.
Is It Smart To Buy Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) Before It Goes Ex-Dividend?
Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) is about to trade ex-dividend in the next day or so. The ex-dividend date occurs one day before the record date which is the day on which shareholders n
Tebao Biotech (688278.SH) will distribute 0.41 yuan per share in 2023. The stock registration date is May 22
Tebao Biotech (688278.SH) announced that the company will implement the 2023 annual equity distribution, distributed per share...
Are Investors Undervaluing Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) By 47%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Xiamen Amoytop Biotech fair value estimate is CN¥112 Current share price of CN¥59.50 suggests Xiamen Amoytop Biotech is potentially 47% under
Tebao Biotech (688278.SH): Net profit of 129 million yuan in the first quarter increased 53.03% year-on-year
Gelonghui, April 22丨Tebao Biotech (688278.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 545 million yuan, up 30.05% year on year; net profit attributable to shareholders of listed companies was 129 million yuan, up 53.03% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 146 million yuan, up 42.90% year on year; basic earnings per share were 0.32 yuan.
Tebao Biotech (688278.SH): Approved as a high-tech enterprise
Gelonghui, April 15, 丨 Tebao Biotech (688278.SH) announced that the company recently received the “High-tech Enterprise Certificate” (certificate number: GR202335100220) jointly issued by the Xiamen Municipal Bureau of Science and Technology, the Xiamen Municipal Finance Bureau, and the Xiamen Municipal Taxation Bureau of the State Administration of Taxation. The issuance period is November 22, 2023, and the certificate is valid for three years. This high-tech enterprise certification is a re-certification carried out after the expiration of the company's original certificate.
There May Be Underlying Issues With The Quality Of Xiamen Amoytop Biotech's (SHSE:688278) Earnings
Last week's profit announcement from Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) was underwhelming for investors, despite headline numbers being robust. Our analysis uncovered some concerning fact
Guojin Securities's April industry allocation: gradually shifting from a “small to medium market growth attack” to a “large market value defense” (with April's top ten gold stocks)
Although the current risks have not been clearly revealed, they are gradually accumulating, and the “cost performance ratio” of investment returns is declining. It is expected that the upward momentum of A-shares in April will probably weaken.
China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6%
Chinese shares advanced on the first day of the trading week as sentiment turned upbeat over positive economic indicators reported on Monday, with retail sales and industrial output both surpassing ex
Xiamen Amoytop Biotech Gets Nod to Market Hepatitis Drug; Shares Up 4%
Xiamen Amoytop Biotech (SHA:688278) received approval from China's National Medical Products Administration to market the drug Pegbin, the company said in a filing with the Shanghai Stock Exchange. Th
If EPS Growth Is Important To You, Xiamen Amoytop Biotech (SHSE:688278) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investment
Guojin Securities: Chronic Hepatitis B Cure Track has broad potential market space and continues to recommend companies that deploy long-acting interferons and related innovative drugs
The chronic hepatitis B cure track is one of the tracks that the trip continues to be optimistic about and recommended. Clinical cure for chronic hepatitis B has now entered a new stage from early exploration to international recognition to rapid and in-depth development.
Tebao Biotech (688278.SH) Performance Report: 2023 net profit of 554 million yuan, a year-on-year increase of 93.14%
Gelonghui, Feb. 23: Tebao Biotech (688278.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 2.1 billion yuan, up 37.55%; operating profit of 680 million yuan, up 67.09% year on year; total profit of 640 million yuan, up 79.77% year on year; realized net profit attributable to owners of the parent company of 554 million yuan, an increase of 93.14% year on year; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 580 million yuan, an increase of 73.86% year on year.
The Recent Pullback Must Have Dismayed Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) Insiders Who Own 52% of the Company
Key Insights Xiamen Amoytop Biotech's significant insider ownership suggests inherent interests in company's expansion The top 3 shareholders own 61% of the company 15% of Xiamen Amoytop Biotech
Are Strong Financial Prospects The Force That Is Driving The Momentum In Xiamen Amoytop Biotech Co., Ltd.'s SHSE:688278) Stock?
Xiamen Amoytop Biotech (SHSE:688278) has had a great run on the share market with its stock up by a significant 35% over the last three months. Given that the market rewards strong financials in the
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Amoytop Biotech Signs Exclusive License Deal for Liver Disease Drug With Alphamab Unit
Xiamen Amoytop Biotech (SHA:688278) signed an exclusive license agreement with Suzhou Alphamab Biotechnology, a unit of Suzhou-based Alphamab Oncology (HKG:9966), for the development, registration, an
Tebao Biotech (688278.SH): Adjust the capital investment amount raised for the fund-raising projects “Protein Drug Production Expansion and R&D Center Construction Project” and the “New Drug Research and Development Project”
Gelonghui (688278.SH) announced on December 6 | Tebao Biotech () announced that on December 6, 2023, the company held the 16th meeting of the 8th board of directors and the 11th meeting of the 8th board of supervisors separately to review and pass the “bill on changing some fund-raising investment projects”, agreeing that the company would change some of the fund-raising investment projects and adjust the amount of capital raised for the fund-raising projects “protein drug production expansion and R&D center construction projects” and “new drug research and development projects”.
A Look At The Intrinsic Value Of Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Xiamen Amoytop Biotech fair value estimate is CN¥49.89 With CN¥42.08 share price, Xiamen Amoytop Biotech appears to be trading close to its e
Analysis
Price Target
No Data
